CHAPTER 1 RESEARCH METHODOLOGY
1.1 MARKET SEGMENTATION & SCOPE
1.1.1 ESTIMATES AND FORECAST TIMELINE
1.2 RESEARCH METHODOLOGY
1.3 INFORMATION PROCUREMENT
1.3.1 PURCHASED DATABASE
1.3.2 GVR’S INTERNAL DATABASE
1.3.3 SECONDARY SOURCES
1.3.4 PRIMARY RESEARCH
1.3.5 DETAILS OF PRIMARY RESEARCH
1.4 INFORMATION OR DATA ANALYSIS
1.4.1 DATA ANALYSIS MODELS
1.5 MARKET FORMULATION & VALIDATION
1.6 MODEL DETAILS
1.6.1 COMMODITY FLOW ANALYSIS
1.6.1.1 APPROACH 1: COMMODITY FLOW APPROACH
1.6.1.2 APPROACH 2: COUNTRY-WISE MARKET ESTIMATION USING BOTTOM-UP APPROACH
1.7 GLOBAL MARKET: CAGR CALCULATION
1.8 RESEARCH ASSUMPTIONS
1.9 LIST OF SECONDARY SOURCES
1.10 LIST OF PRIMARY SOURCES
1.11 OBJECTIVES
1.11.1 OBJECTIVE 1:
1.11.2 OBJECTIVE 2:
1.12 LIST OF ABBREVIATIONS
CHAPTER 2 MARKET DEFINITIONS
CHAPTER 3 EXECUTIVE SUMMARY
3.1 MARKET SUMMARY
CHAPTER 4 GLOBAL 3D PRINTED DRUGS MARKET VARIABLES, TRENDS, & SCOPE
4.1 3D PRINTED DRUGS MARKET LINEAGE OUTLOOK
4.1.1 PARENT MARKET OUTLOOK
4.2 PENETRATION AND GROWTH PROSPECT MAPPING
4.3 REGULATORY FRAMEWORK
4.4 MARKET DRIVER ANALYSIS
4.4.1 RISING USAGE OF 3D PRINTING IN THE MEDICAL INDUSTRIES
4.4.2 INCREASING ADOPTION OF PERSONALIZED DRUGS
4.4.3 MULTIPLE APPLICATIONS OF 3D PRINTING IN VARIOUS INDUSTRIES
4.4.4 HIGH DEMAND FOR INSTANTANEOUS SOLUBLE TABLETS
4.4.5 OUTBREAK OF COVID-19
4.5 MARKET RESTRAINT ANALYSIS
4.5.1 LIMITATIONS OF 3D PRINTED MEDICINES
4.5.2 LACK OF GOVERNMENT REGULATIONS FOR 3D PRINTED PRODUCTS
4.6 MARKET OPPORTUNITY ANALYSIS
4.6.1 RISING AWARENESS AND ADOPTION OF THE 3D PRINTING TECHNOLOGY
4.7 PORTER’S FIVE FORCES ANALYSIS
4.8 PIPELINE ANALYSIS
CHAPTER 5 3D PRINTED MARKET - SEGMENT ANALYSIS, BY TECHNOLOGY, 2019 - 2033
5.1 GLOBAL 3D PRINTED DRUGS MARKET: TECHNOLOGY MOVEMENT ANALYSIS
5.2 INKJET PRINTING
5.2.1 INKJET PRINTING MARKET ESTIMATES AND FORECAST, 2019 - 2033
5.3 FUSED DEPOSITION MODELING
5.3.1 FUSED DEPOSITION MODELING MARKET ESTIMATES AND FORECAST, 2019 - 2033
5.4 STEREOLITHOGRAPHY
5.4.1 STEREOLITHOGRAPHY MARKET ESTIMATES AND FORECAST, 2019 - 2033
5.5 ZIPDOSE TECHNOLOGY
5.5.1 ZIPDOSE TECHNOLOGY MARKET ESTIMATES AND FORECAST, 2019 - 2033
CHAPTER 6 3D PRINTED DRUGS MARKET - SEGMENT ANALYSIS, BY APPLICATION, 2019 - 2033
6.1 GLOBAL 3D PRINTED DRUGS MARKET: APPLICATION MOVEMENT ANALYSIS
6.2 ORTHOPEDIC
6.2.1 ORTHOPEDIC MARKET ESTIMATES AND FORECAST, 2019 - 2033
6.3 NEUROLOGY
6.3.1 NEUROLOGY MARKET ESTIMATES AND FORECAST, 2019 - 2033
6.4 DENTAL
6.4.1 DENTAL MARKET ESTIMATES AND FORECAST, 2019 - 2033
6.5 OTHERS
6.5.1 OTHER MARKET ESTIMATES AND FORECAST, 2019 - 2033
CHAPTER 7 3D PRINTED DRUGS MARKET- SEGMENT ANALYSIS, BY END-USER, 2019 - 2033
7.1 3D PRINTED DRUGS MARKET: END-USER MOVEMENT ANALYSIS
7.2 HOSPITALS & CLINICS
7.2.1 HOSPITALS & CLINICS MARKET ESTIMATES AND FORECAST, 2019 - 2033
7.3 RESEARCH LABORATORIES
7.3.1 RESEARCH LABORATORIES MARKET ESTIMATES AND FORECAST, 2019 - 2033
7.4. OTHERS
7.4.1 OTHER MARKET ESTIMATES AND FORECAST, 2019 - 2033
CHAPTER 8 3D PRINTED DRUGS MARKET: - SEGMENT ANALYSIS, BY REGION, 2019 - 2033
8.1 3D PRINTED DRUGS MARKET: REGIONAL MOVEMENT ANALYSIS
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.2.2 U.S.
8.2.2.1 U.S. MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.2.3 CANADA
8.2.3.1 CANADA MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.3 EUROPE
8.3.1 EUROPE MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.3.2 U.K.
8.3.2.1 U.K. MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.3.3. GERMANY
8.3.3.1 GERMANY MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.3.4 SPAIN
8.3.4.1 SPAIN MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.3.5 FRANCE
8.3.5.1 FRANCE MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.3.6 ITALY
8.3.6.1 ITALY MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.4.2 JAPAN
8.4.2.1 JAPAN MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.4.3 CHINA
8.4.3.1 CHINA MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.4.4 INDIA
8.4.4.1 INDIA MARKET ESTIMATES AND FORECAST, 2018 - 2030
8.4.5 SOUTH KOREA
8.4.5.1 SOUTH KOREA MARKET ESTIMATES AND FORECAST, 2018 - 2030
8.5 LATIN AMERICA
8.5.1 LATIN AMERICA MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.5.2 BRAZIL
8.5.2.1 BRAZIL MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.5.3 MEXICO
8.5.3.1 MEXICO MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.6 MIDDLE EAST & AFRICA (MEA)
8.6.1 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.6.2. SOUTH AFRICA
8.6.2.1 SOUTH AFRICA MARKET ESTIMATES AND FORECAST, 2019 - 2033
8.6.3 SAUDI ARABIA
8.6.3.1 SAUDI ARABIA MARKET ESTIMATES AND FORECAST, 2019 - 2033
CHAPTER 9 COMPETITIVE LANDSCAPE
9.1 PUBLIC COMPANIES
9.1.1 COMPANY MARKET POSITION ANALYSIS
9.1.2 COMPETITIVE DASHBOARD ANALYSIS
9.1.3 STRATEGIC FRAMEWORK
9.2 PRIVATE COMPANIES
9.2.1 LIST OF KEY EMERGING COMPANIES/TECHNOLOGY DISRUPTORS/INNOVATORS
9.2.2 REGIONAL NETWORK MAP
9.3 COMPANY PROFILES
9.3.1 APRECIA PHARMACEUTICALS LLC
9.3.1.1 COMPANY OVERVIEW
9.3.1.2 ALERE, INC.
9.3.1.3 FINANCIAL PERFORMANCE
9.3.1.4 PRODUCT BENCHMARKING
9.3.1.5 STRATEGIC INITIATIVES
9.3.2 AFFINITY THERAPEUTICS
9.3.2.1 COMPANY OVERVIEW
9.3.2.2 FINANCIAL PERFORMANCE
9.3.2.3 PRODUCT BENCHMARKING
9.3.2.4 STRATEGIC INITIATIVES
9.3.3 EXTEND BIOSCIENCES
9.3.3.1 COMPANY OVERVIEW
9.3.3.2 FINANCIAL PERFORMANCE
9.3.3.3 PRODUCT BENCHMARKING
9.3.3.4 STRATEGIC INITIATIVES
9.3.4 GLAXOSMITHKLINE PLC
9.3.4.1 COMPANY OVERVIEW
9.3.4.2 FINANCIAL PERFORMANCE
9.3.4.3 PRODUCT BENCHMARKING
9.3.4.4 STRATEGIC INITIATIVES
9.3.5 MERCK
9.3.5.1 COMPANY OVERVIEW
9.3.5.2 FINANCIAL PERFORMANCE
9.3.5.3 PRODUCT BENCHMARKING
9.3.5.4 STRATEGIC INITIATIVES
9.3.6 BIODURO
9.3.6.1 COMPANY OVERVIEW
9.3.6.2 FINANCIAL PERFORMANCE
9.3.6.3 PRODUCT BENCHMARKING
9.3.6.4 STRATEGIC INITIATIVES
9.3.7 OSMOTICA PHARMACEUTICALS
9.3.7.1 COMPANY OVERVIEW
9.3.7.2 FINANCIAL PERFORMANCE
9.3.7.3 PRODUCT BENCHMARKING
9.3.7.4 STRATEGIC INITIATIVES
9.3.8 HEWLETT PACKARD CARIBE
9.3.8.1 COMPANY OVERVIEW
9.3.8.2 FINANCIAL PERFORMANCE
9.3.8.3 PRODUCT BENCHMARKING
9.3.8.4 STRATEGIC INITIATIVES
9.3.9 ASTRAZENECA
9.3.9.1 COMPANY OVERVIEW
9.3.9.2 FINANCIAL PERFORMANCE
9.3.9.3 PRODUCT BENCHMARKING
9.3.9.4 STRATEGIC INITIATIVES
9.3.10 CYCLE PHARMACEUTICALS
9.3.10.1 COMPANY OVERVIEW
9.3.10.2 FINANCIAL PERFORMANCE
9.3.10.3 PRODUCT BENCHMARKING
9.3.10.4 STRATEGIC INITIATIVES
9.3.11 FABRX LTD
9.3.11.1 COMPANY OVERVIEW
9.3.11.2 FINANCIAL PERFORMANCE
9.3.11.3 PRODUCT BENCHMARKING
9.3.11.4 STRATEGIC INITIATIVES
9.3.12 OTHERS
9.3.12.1 COMPANY OVERVIEW
9.3.12.2 FINANCIAL PERFORMANCE
9.3.12.3 PRODUCT BENCHMARKING
9.3.12.4 STRATEGIC INITIATIVES
著作権 ©2022 無断複写・転載を禁じます
